{"id":5503,"date":"2018-07-01T12:40:32","date_gmt":"2018-07-01T10:40:32","guid":{"rendered":"http:\/\/wordpress.p545550.webspaceconfig.de\/uncategorized\/leukocare-und-boehringer-ingelheim-haben-einen-lizenzvertrag-im-bereich-der-veterinaermedizinischen-diagnostik-unterzeichnet\/"},"modified":"2020-07-03T09:39:03","modified_gmt":"2020-07-03T07:39:03","slug":"leukocare-und-boehringer-ingelheim-haben-einen-lizenzvertrag-im-bereich-der-veterinaermedizinischen-diagnostik-unterzeichnet","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/leukocare-und-boehringer-ingelheim-haben-einen-lizenzvertrag-im-bereich-der-veterinaermedizinischen-diagnostik-unterzeichnet\/","title":{"rendered":"LEUKOCARE and Boehringer Ingelheim enter into a license agreement in the field of veterinary diagnostics"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

LEUKOCARE and Boehringer Ingelheim enter into a license agreement in the field of veterinary diagnostics<\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]July 2018[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”5492″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 LEUKOCARE AG[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]LEUKOCARE grants a license to Laboratorios Liomont<\/strong>
\nBiotechnology company LEUKOCARE AG, Germany, and Laboratorios Liomont S.A., Mexico, have entered into a license agreement in the field of biosimilar development. Under the terms of this agreement, Liomont will have access to LEUKOCARE\u00b4s SPS\u00ae technology platform and know-how to develop a novel \u00adformulation for one of Liomont\u2019s pharmaceutical products.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]Biotechnology company LEUKOCARE has gained another important partner for its Stabilizing and Protecting Solutions (SPS\u00ae) technologies. As the company from Martins\u00adried near Munich announced, LEUKOCARE has signed a license agreement with \u00adBoehringer Ingelheim. Based on this agreement, the animal health division of pharmaceutical company Boehringer Ingelheim will use LEUKO\u00adCARE\u2019s SPS\u00ae formulation techno\u00adlogies to deploy and stabilize biological reagents in a new veterinary diagnostics \u00adpro\u00adduct. License and payment terms have not been disclosed by the partners.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote”][vc_column_inner][vc_single_image image=”5494″ img_size=”155×155″ alignment=”center” style=”vc_box_circle_2″][vc_column_text el_class=”gco-magazine–picture-discription-blank”]<\/p>\n

Michael Scholl, CEO, LEUKO\u00adCARE<\/p>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine-copyright-blank”]<\/p>\n

\u00a9 LEUKOCARE AG<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]Michael Scholl, CEO of LEUKOCARE, commented: \u201cAfter having worked with \u00adBoehringer Ingelheim for a long time and being closely involved in their development activities, we are very pleased to be able to support our partner with our SPS\u00ae techno\u00adlogies in a specific application. This demonstrates once again the high quality of our SPS\u00ae formulation technology platform as well as our development expertise.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n